Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Tesamorelin: Evidence Summary
Evidence summary for Tesamorelin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Tesamorelin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| HIV-associated lipodystrophy | Tier A | 5 | FDA-approved indication — reduces trunk fat by 15-18% in pivotal trials |
| Body composition (non-HIV) | Tier B | 3 | Reduces visceral adipose tissue and improves lipid profiles in non-HIV populations |
| Cognitive function (MCI) | Tier C | 1 | Phase II trial showed improved executive function in adults with mild cognitive impairment |